Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trabectedin maintenance after pegylated liposomal doxorubicin plus trabectedin in relapsed ovarian cancer
2017-000987-14Phase 2Completed
- Sponsor
- Azienda Ospedaliera Cannizzaro
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trabectedin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Azienda Ospedaliera Cannizzaro. Primary endpoint: Progression-free survival. Started Sep 2021; status: completed.
02
Drugs
trabectedin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-000987-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000987-14.